Graham L. Smith

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Research Studies, HIV Research and Treatment, Synthesis and biological activity

Most-Cited Works

• → Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations(2014)574 cited
• → Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib(2014)117 cited
• → Development of Scalable Syntheses of Selective PI3K inhibitors(2011)45 cited
• → Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors(2011)43 cited
• → Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity(2011)39 cited
• → 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors(2010)33 cited
• → Acidic triazoles as soluble guanylate cyclase stimulators(2011)27 cited
• → Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK(2010)23 cited
• → Pharmacodynamics of Mivacurium during Desflurane Anesthesia(1994)5 cited
• → Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.(2013)4 cited